In vitro inhibition of methadone and oxycodone cytochrome P450-dependent metabolism: Reversible inhibition by H2-receptor agonists and proton-pump inhibitors

Journal of Analytical Toxicology

Volumn 37, Issue 8, 2013, Pages 476-485

  Moody, David E ^a   Liu, Fenyun ^a   Fang, Wenfang B ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYLIDENE 1,5 DIMETHYL 3,3 DIPHENYLPYRROLIDINE; CIMETIDINE; COMPLEMENTARY DNA; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C18; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; ESOMEPRAZOLE; FAMOTIDINE; HISTAMINE H2 RECEPTOR AGONIST; LANSOPRAZOLE; METHADONE; NIZATIDINE; NOROXYCODONE; OMEPRAZOLE; OXYCODONE; OXYMORPHONE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; RANITIDINE; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BINDING; DRUG INHIBITION; DRUG METABOLISM; ENANTIOMER; ENZYME ASSAY; ENZYME INHIBITION; ENZYME SUBSTRATE; HUMAN; IC 50; IN VITRO STUDY; LIVER MICROSOME; METABOLIC INHIBITION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PROTEIN EXPRESSION;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DNA, COMPLEMENTARY; DRUG INTERACTIONS; HISTAMINE AGONISTS; HISTAMINE H2 ANTAGONISTS; HUMANS; METHADONE; MICROSOMES, LIVER; OXYCODONE; PROTON PUMP INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STEREOISOMERISM; TANDEM MASS SPECTROMETRY;

EID: 84888884272     PISSN: 01464760     EISSN: 19452403     Source Type: Journal    
DOI: 10.1093/jat/bkt060     Document Type: Article

References (64)

1. Maxwell, J.C., McCance-Katz, E.F. (2010) Indicators of buprenorphine and methadone use and abuse: what do we know. American Journal of Addictions, 19, 73-88.
2. CDC. (2012) Vital signs: risk for overdose from methadone used for pain relief-United States, 1999-2010. MMWR. Morbidity and Mortality Weekly Report, 61, 493-497.
3. Moody, D.E. (2013) Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opinion in Drug Metabolism and Toxicology, 9, 675-697.
4. Armstrong, S.C., Cozza, K.L. (2003) Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics, 44, 515-520.
5. Cone, E.J., Fant, R.V., Rohay, J.M., Caplan, Y.H., Ballina, M., Reder, R.F. et al. (2004) Oxycodone involvement in drug abuse deaths. II. Evidence for toxic multiple drug-drug interactions. Journal of Analytical Toxicology, 28, 616-624.
6. McCance-Katz, E.F., Sullivan, L.E., Nallani, S. (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. American Journal of Addictions, 19, 4-16.
7. Fishbain, D.A., Lewis, J.E., Gao, J. (2010) Allegations of medical malpractice in chronic opioid analgesic therapy possibly related to collaborative/ split treatment and the P-450 enzyme system: forensic case report. Pain Medicine, 11, 1419-1425.
8. Hisaka, A., Ohno, Y., Yamamoto, T., Suzuki, H. (2010) Prediction of pharmacokinetic drug-drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology and Therapeutics, 125, 230-248.
9. Zhang, L., Reynolds, K.S., Zhao, P., Huang, S.M. (2010) Drug interactions evaluation: an integrated part of risk assessment of therapeutics. Toxicology and Applied Pharmacology, 243, 134-145.
10. Kristensen, K., Blemmer, T., Angelo, H.R., Christrup, L.L., Drenck, N.E., Rasmussen, S.N. et al. (1996) Stereoselective pharmacokinetics of methadone in chronic pain patients. Therapeutic Drug Monitoring, 18, 221-227.
11. Callahan, R.J., Au, J.D., Paul, M., Liu, C., Yost, C.S. (2004) Functional inhibition by methadone of N-methyl-D-aspartate receptors expressed in Xenopus oocytes: stereospecific and subunit effects. Anesthesia and Analgesia, 98, 653-659.
12. Eap, C.B., Crettol, S., Rougier, J.S., Schlapfer, J., Grilo, L.S., Deglon, J.J. et al. (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clinical Pharmacology and Therapeutics, 81, 719-728.
13. Moody, D.E., Alburges, M.E., Parker, R.J., Collins, J.M., Strong, J.M. (1997) The involvement of cytochrome P450 3A in the N-demethylation of l-a-acetylmethadol (LAAM), norLAAM and methadone. Drug Metabolism and Disposition 25, 1347-1353.
14. Chang, Y., Fang,W.B., Lin, S.N., Moody, D.E. (2011) Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation. Basic and Clinical Pharmacology and Toxicology, 108, 55-62.
15. Iribarne, C., Berthou, F., Baird, S., Dreano, Y., Picart, D., Bail, J.P. et al. (1996) Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chemical Research in Toxicology, 9, 365-373.
16. Gerber, J.G., Rhodes, R.J., Gal, J. (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality, 16, 36-44.
17. Totah, R.A., Sheffels, P., Roberts, T., Whittington, D., Thummel, K., Kharasch, E.D. (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology, 108, 363-374.
18. Lalovic, B., Phillips, B., Risler, L.L., Howald, W., Shen, D.D. (2004) Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metabolism and Disposition, 32, 447-454.
19. Fang, W.B., Lofwall, M.R., Walsh, S.L., Moody, D.E. (2013) Determination of oxycodone, noroxycodone and oxymorphone by high performance liquid chromatography-electrospray ionizationtandem mass spectrometry in human matrices: in vivo and in vitro applications. Journal of Analytical Toxicology, 37, 337-344.
20. Lalovic, B., Kharasch, E.D., Hoffer, C., Risler, L., Liu-Chen, L.Y., Shen, D.D. (2006) Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: Role of circulating active metabolites. Clinical Pharmacology and Therapeutics, 79, 461-479.
21. Kreek, M.J., Garfield, J.W., Gutjahr, C.L., Giusti, L.M. (1976) Rifampin-induced methadone withdrawal. New England Journal of Medicine, 294, 1104-1106.
22. Eap, C.B., Buclin, T., Baumann, P. (2002) Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clinical Pharmacokinetics, 41, 1153-1193.
23. Saber-Tehrani, A.S., Bruce, R.D., Altice, F.L. (2011) Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. The American Journal of Drug and Alcohol Abuse, 37, 1-11.
24. Kapur, B.M., Hutson, J.R., Chibber, T., Luk, A., Selby, P. (2011) Methadone: a review of drug-drug and pathophysiological interactions. Critical Reviews in Clinical Laboratory Sciences, 48, 171-195.
25. Overholser, B.R., Foster, D.R. (2011) Opioid pharmacokinetic drug- drug interactions. The American Journal of Managed Care, 17 (Suppl 11), S276-S287.
26. Samer, C.F., Daali, Y., Wagner, M., Hopfgartner, G., Eap, C.B., Rebsamen, M.C. et al. (2010) The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone. British Journal of Pharmacology, 160, 907-918.
27. Nieminen, T.H., Hagelberg, N.M., Saari, T.I., Pertovaara, A., Neuvonen, M., Laine, K. et al. (2009) Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology, 110, 1371-1378.
28. Nieminen, T.H., Hagelberg, N.M., Saari, T.I., Neuvonen, M., Laine, K., Neuvonen, P.J. et al. (2010) St John's wort greatly reduces the concentration of oral oxycodone. European Journal of Pain, 14, 854-859.
29. Nieminen, T.H., Hagelberg, N.M., Saari, T.I., Neuvonen, M., Neuvonen, P.J., Laine, K. et al. (2010) Grapefruit juice enhances the exposure to oral oxycodone. Basic and Clinical Pharmacology and Toxicology, 107, 782-788.
30. Nieminen, T.H., Hagelberg, N.M., Saari, T.I., Neuvonen, M., Neuvonen, P.J., Laine, K. et al. (2010) Oxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavir. European Journal of Clinical Pharmacology, 66, 977-985.
31. Flockhart, D.A., Desta, Z., Mahal, S.K. (2000) Selection of drugs to treat gastro-oesophageal reflux disease-the role of drug interactions. Clinical Pharmacokinetics, 39, 295-309.
32. Ogawa, R., Echizen, H. (2010) Drug-drug interaction profiles of proton pump inhibitors. Clinical Pharmacokinetics, 49, 509-533.
33. Neff, J.A., Moody, D.E. (2001) Differential N-demethylation of l-a-acetylmethadol (LAAM) and norLAAM by cytochrome P450 s 2B6, 2C18, and 3A4. Biochemical and Biophysical Research Communications, 284, 751-756.
34. Chang, Y., Moody, D.E., McCance-Katz, E.F. (2006) Novel metabolites of buprenorphine detected in human liver microsomes and human urine. Drug Metabolism and Disposition, 34, 440-448.
35. Nelson, A.C., Huang, W., Moody, D.E. (2001) Variables in human liver microsome preparation: impact on the kinetics of l-a-acetylmethadol (LAAM) N-demethylation and dextromethorphan O-demethylation. Drug Metabolism and Disposition, 29, 319-325.
36. Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.L. (1951) Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
37. Moody, D.E., Lin, S.N., Chang, Y., Lamm, L., Greenwald, M.K., Ahmed, M.S. (2008) An enantiomer selective liquid chromatography-tandem mass spectrometry method for methadone and EDDP validated for use in human plasma, urine and liver microsomes. Journal of Analytical Toxicology, 32, 208-219.
38. FDA, US (2006) Guidance for Industry-Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling (Draft Guidance). http://www.fda.gov/cder/ guidance/index.htm (4 January 2011, date last accessed).
39. Zvyaga, T., Chang, S.Y., Chen, C., Yang, Z., Vuppugalla, R., Hurley, J. et al. (2012) Evaluation of six proton pump inhibitors as inhibitors of various human cytochromes P450: focus on cytochrome P450 2C19. Drug Metabolism and Disposition, 40, 1698-1711.
40. Cheng, Y., Prusoff, W.H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology, 22, 3099-3108.
41. Chang, Y., Moody, D.E. (2009) Glucuronidation of buprenorphine and norbuprenorphine by human liver microsomes and UDPglucuronosyltransferases. Drug Metabolism Letters, 3, 101-107.
42. Fowler, S., Zhang, H. (2008) In vitro evaluation of reversible and irreversible cytochrome P450 inhibition: current status on methodologies and their utility for predicting drug-drug interactions. The AAPS Journal, 10, 410-424.
43. Hollenberg, P.F., Kent, U.M., Bumpus, N.N. (2008) Mechanism-based inactivation of human cytochromes P450s: experimental characterization, reactive intermediates, and clinical implications. Chemical Research in Toxicology, 21, 189-205.
44. Grimm, S.W., Einolf, H.J., Hall, S.D., He, K., Lim, H.K., Ling, K.H.J. et al. (2009) The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition, 37, 1355-1370.
45. Reese, M.J., Wurm, R.M., Muir, K.T., Generaux, G.T., St John-Williams, L., McConn, D.J. (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metabolism and Disposition, 36, 1198-1201.
46. Yeung, C.K., Fujioka, Y., Hachad, H., Levy, R.H., Isoherranen, N. (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clinical Pharmacology and Therapeutics, 89, 105-113.
47. Knodell, R.G., Holtzman, J.L., Crankshaw, D.L., Steele, N.M., Stanley, L.N. (1982) Drug metabolism by rat and human hepatic microsomes in response to interaction with H2-receptor antagonists. Gastroenterology, 82, 84-88.
48. Reilly, P.E.B., Mason, S.R., Gillam, E.M.J. (1988) Differential inhibition of human liver phenacetin O-deethylation by histamine and four histamine H2-receptor antagonists. Xenobiotica, 18, 381-387.
49. Martinez, C., Albet, C., Agundez, J.A.G., Herrero, E., Carrillo, J.A., Marquez, M. et al. (1999) Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clinical Pharmacology and Therapeutics, 65, 369-376.
50. Furuta, S., Kamada, E., Suzuki, T., Sugimoto, T., Kawabata, Y., Shinozaki, Y. et al. (2001) Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica, 31, 1-10.
51. Madeira, M., Levine, M., Chang, T.K., Mirfazaelian, A., Bellward, G.D. (2004) The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6. Drug Metabolismand Disposition, 32, 460-467.
52. Tingle, M.D., Coleman, M.D., Park, B.K. (1991) The effect of preincubation with cimetidine on the N-hydroxylation of dapsone by human liver microsomes. British Journal of Clinical Pharmacology, 32, 120-123.
53. Winter, H.R., Wang, Y., Unadkat, J.D. (2000) CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metabolism and Disposition, 28, 865-868.
54. Ganesan, S., Sahu, R., Walker, L.A., Tekwani, B.L. (2010) Cytochrome P450-dependent toxicity of dapsone in human erythrocytes. Journal of Applied Toxicology, 30, 271-275.
55. VandenBranden, M., Ring, B.J., Binkley, S.N., Wrighton, S.A. (1996) Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor. Pharmacogenetics, 6, 81-91.
56. Ko, J.-W., Sukhova, N., Thacker, D., Chen, P., Flockhart, D.A. (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition, 25, 853-862.
57. Li, X.Q., Andersson, T.B., Ahlstrom, M., Weidolf, L. (2004) Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metabolism and Disposition, 32, 821-827.
58. Liu, K.H., Kim, M.J., Shon, J.H., Moon, Y.S., Seol, S.Y., Kang, W. et al. (2005) Sterioselective inhibition of cytochrome P450 forms by lansoprazole and omeprazole in vitro. Xenobiotica, 35, 27-38.
59. Ogilvie, B.W., Yerino, P., Kazmi, F., Buckley, D.B., Rostami-Hodjegan, A., Paris, B.L. et al. (2011) The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel. Drug Metabolism and Disposition, 39, 2020-2033.
60. Meyer, M.R.,Maurer, H.H. (2011) Absorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse. Pharmacogenomics, 12, 215-233.
61. Schulz, M., Schmoldt, A. (2003) Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Die Pharmazie, 58, 447-474.
62. Suzuki, K., Doki, K., Homma, M., Tamaki, H., Hori, S., Ohtani, H. et al. (2009) Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. British Journal of Clinical Pharmacology, 67, 44-49.
63. Somogyi, A., Gugler, R. (1983) Clinical pharmacokinetics of cimetidine. Clinical Pharmacokinetics, 8, 463-495.
64. Andersson, T., Weidolf, L. (2008) Stereoselective disposition of proton pump inhibitors. Clinical Drug Investigation, 28, 263-279.